Greenwich LifeSciences (GLSI) Total Current Liabilities (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Total Current Liabilities of $5.8 million for Q4 2025, up 259.11% on a QoQ basis from $1.6 million in Q3 2025, and up 82.87% year-over-year from $3.2 million in Q4 2024.
Greenwich LifeSciences (GLSI) Total Current Liabilities (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $5.8 million for Q4 2025.
- Quarterly Total Current Liabilities rose 82.87% year-over-year to $5.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.8 million (up 82.87% YoY) and the FY2025 annual result came in at $5.8 million, up 82.87% from the prior year.
- Total Current Liabilities was $5.8 million for Q4 2025 at Greenwich LifeSciences, up from $1.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $5.8 million in Q4 2025 and bottomed at $229134.0 in Q2 2022.
- A 5-year average of $1.0 million and a median of $422365.0 in 2021 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities plunged 71.84% — and 2024, when it surged 981.89%.
- Greenwich LifeSciences' Total Current Liabilities stood at $385172.0 in 2021, then tumbled by 31.74% to $262905.0 in 2022, then increased by 11.98% to $294406.0 in 2023, then jumped by 981.89% to $3.2 million in 2024, then jumped by 82.87% to $5.8 million in 2025.
- Business Quant data shows GLSI's Total Current Liabilities at $5.8 million in Q4 2025, $1.6 million in Q3 2025, and $1.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | 5.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.82 Mn |
| Sep 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 3.19 Mn |
| Sep 30, 2024 | 842,384.00 |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 389,611.00 |
| Dec 31, 2023 | 294,406.00 |
| Sep 30, 2023 | 297,287.00 |
| Jun 30, 2023 | 301,546.00 |
| Mar 31, 2023 | 235,575.00 |
| Dec 31, 2022 | 262,905.00 |
| Sep 30, 2022 | 237,879.00 |
| Jun 30, 2022 | 229,134.00 |
| Mar 31, 2022 | 241,168.00 |
| Dec 31, 2021 | 385,172.00 |
| Sep 30, 2021 | 455,119.00 |
| Jun 30, 2021 | 652,594.00 |
| Mar 31, 2021 | 673,122.00 |